Comparing the current results to its competitors, Alterity Therapeutics Limited reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 17.21 %, recorded in the same quarter.
Alterity Therapeutics Limited's Comment on Competition and Industry Peers
The company operates in the highly competitive pharmaceutical industry and anticipates facing competition across all research areas. Its product ATH434, if approved for treating multiple system atrophy (MSA), will enter a market with numerous global competitors, including major pharmaceutical companies, biotechnology firms, universities, and research institutions. These competitors may develop more effective technologies and products or render the company's offerings obsolete or non-competitive. Many competitors possess greater financial resources, research capabilities, screening, technical expertise, manufacturing capacity, marketing capabilities, and more experience with non-clinical and human clinical trials and regulatory approvals.
April 29, 2024
Alterity Therapeutics, a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, has recently presented new data showcasing the potential of their investigational drug, ATH434, in the treatment of Friedreich s Ataxia. In addition to this breakthrough, the company has also received positive recommendations from their Phase 2 Data Monitoring Committee to continue the clinical trial as planned, indicating promising progress.ATH434 has shown potential as an iron chaperone, redistributing iron to target areas within the body. This iron redistribution mechanism could potentially provide therapeutic benefits in treating Friedreich s Ataxia, a rare neurodegenerative d...
Publicly Traded Peers of Alterity Therapeutics Limited
Acadia Pharmaceuticals Inc Share Performance
+33.66%
This Quarter
Acadia Pharmaceuticals Inc
Profile
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.
Crinetics Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. They primarily generate revenue through the sale of their developed drugs and potential partnerships with other pharmaceutical companies.
Intra Cellular Therapies Inc operates as a biopharmaceutical company that focuses on the discovery and development of innovative therapeutics for the treatment of neuropsychiatric and neurodegenerative diseases. Their business model involves conducting research and clinical trials to validate the efficacy and safety of their drug candidates. Once successful, they aim to gain regulatory approvals, form strategic partnerships, and commercialize their products to provide medical solutions for patients suffering from these challenging conditions.
Sources:
Alterity Therapeutics Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alterity Therapeutics Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
